Cytogenetic Analysis of a Pseudoangiomatous Pleomorphic/Spindle Cell Lipoma

Panagopoulos, Ioannis; Gorunova, Ludmila; Lobmaier, Ingvild; Andersen, Hege Kilen; Bjerkehagen, Bodil; Heim, Sverre

doi:10.21873/anticanres.11557

Cited by 6 publications

(6 citation statements)

References 16 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the existing studies, lncRNA DLEU1 as a new research focus, is closely related to the tumor. Most studies have revealed that there is deletion of DLEU1 gene that maps to a region at chromosoma 13q14.3 in some solid tumors and hematopoietic malignancies, such as atypical or classical spindle cell lipomas, chronic lymphocytic leukemia, and small lymphocytic lymphoma . In addition, lncRNA DLEU1 can also work as an oncogene in gastric cancer and ovarian carcinoma .…”

Section: Introductionmentioning

confidence: 99%

“…Most studies have revealed that there is deletion of DLEU1 gene that maps to a region at chromosoma 13q14.3 in some solid tumors and hematopoietic malignancies, such as atypical or classical spindle cell lipomas, chronic lymphocytic leukemia, and small lymphocytic lymphoma. [6][7][8][9][10] In addition, lncRNA DLEU1 can also work as an oncogene in gastric cancer and ovarian carcinoma. 11,12 However, the role and effect mechanism of lncRNA DLEU1 in endometrial carcinoma remain unknown.…”

mentioning

confidence: 99%

See 1 more Smart Citation

lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR

Wang

Chen

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

lncRNA DLEU1 as a non-coding gene, involves in the occurrence and development of multiple tumors. However, there is no related report in endometrial carcinoma. In order to focus on the role and mechanism of lncRNA DLEU1 in endometrial carcinoma, we used qRT-PCR to detect the expression of lncRNA DLEU1 and found that lncRNA DLEU1 was highly expressed in endometrial carcinoma compared to normal endometrium. Moreover, compared to Ishikawa and KLE, lncRNA DLEU1 was higher in HEC-1B. In addition, up-regulation of lncRNA DLEU1 promoted cell viability, migration, invasion, and reduced the proportion of apoptosis. Otherwise, down-regulation of lncRNA DLEU1 produced opposite results. Xenograft nude mice model assay showed that lncRNA DLEU1 can promote tumorigenesis in vivo. RiP confirmed that lncRNA DLEU1 could bind to mTOR. The rescue experiments revealed that silence of mTOR after up-regulation of lncRNA DLEU1 resulted in decrease of cell viability, migration, and invasion and increase of apoptosis. The expression changes of PI3K, AKT1, p70S6K, rpS6, GSK3β, STAT3, and Bcl-xl were consistent with lncRNA DLEU1 and mTOR in Western blot. Thus, we suggest that lncRNA DLEU1 combines with mTOR and then increases the expression of PI3K/AKT/mTOR pathway to promote endometrial carcinoma tumorigenesis and progression. The present discovery has probability to provide a biomarker and lay the foundation for targeted therapy of endometrial carcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR

Wang

Chen

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…Although the deletion of ch13q14 where human DLEU1 gene is localized in certain types of cancers supports the notion that DLEU1 is a tumor suppressor [ 1 – 4 ], the absence of DLEU1 gene in mouse ch13q14, together with the presence of at least several other tumor suppressor genes in this chromosomal locus, dampen the significance of loss of DLEU1 expression in tumorigenesis [ 23 , 24 ]. In contrast, increasing studies focusing on DLEU1 presented convincing evidence that DLEU1 is a pan-cancer oncogene.…”

Section: Discussionmentioning

confidence: 99%

“…Increasing studies demonstrate aberrant expression of long non-coding RNAs (lncRNAs) in cancers, supporting their role as biomarkers for cancer diagnosis and prognosis. The lncRNA deleted in lymphocytic leukemia 1 (DLEU1) is encoded by a gene localized in chromosome 13q14.3, a chromosomal region frequently deleted in spindle cell lipoma and other hematological malignancies [ 1 – 4 ], suggesting it may be a tumor suppressor. However, recent studies reveal oncogenic activities of DLEU1: it is up-regulated in a panel of human cancers, correlates with worse prognosis, and promotes various malignant phenotypes [ 5 – 12 ].…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2

Chen

劉

et al. 2022

Cell Death Dis

View full text Add to dashboard Cite

Earlier studies have suggested deleted in lymphocytic leukemia 1 (DLEU1), a long non-coding RNA, is a prognostic biomarker for breast cancer. Here we explored the malignant behaviors and underlying mechanisms regulated by DLEU1 in breast cancer. We demonstrated that up-regulation of DLEU1 was detected in breast cancer tissues and cells, particularly in tumors of higher malignancy. DLEU1 knockdown inhibited the growth and the motility of breast cancer cells. Mechanistically, DLEU1 interacted with HIF-1α to collectively activate the transcription of CKAP2. By activating ERK and STAT3 signaling, CKAP2 essentially mediated the pro-tumor activities of DLEU1. In vivo, depletion of DLEU1 inhibited xenograft growth and metastasis of breast cancer cells. Therefore, DLEU1, by acting as a coactivator for HIF-1α, up-regulates CKAP2 expression and promotes malignancy of breast cancer. Targeting DLEU1, HIF-1α, or CKAP2 may thus benefit breast cancer treatment.

show abstract

“…More recently, DLEU2 has been reported to be abnormally expressed in many malignant tumors. For example, DLEU2 is downregulated in chronic lymphocytic leukemia (CLL) [ 6 ], pleomorphic liposarcoma (PL) [ 9 ], Pseudoangiomatous Pleomorphic/Spindle Cell Lipoma [ 10 ], pediatric AML [ 8 ], and breast cancer (BC) [ 11 ]. However, most reports have shown upregulation of DLEU2 in cancers, including endometrial cancer(EC) [ 12 ], renal clear cell carcinoma(ccRCC) [ 13 ], esophageal cancer (ESCA) [ 14 ], pancreatic cancer (PC) [ 15 ], glioma [ 16 ], gastric cancer(GC) [ 17 ], non-small cell lung cancer (NSCLC) [ 18 ], thyroid cancer(TC) [ 19 ], and prostate cancer (PCa) [ 20 ].…”

Section: Dleu2 In Cancermentioning

confidence: 99%

Deleted in lymphocytic leukemia 2 (DLEU2): a possible biomarker that holds promise for future diagnosis and treatment of cancer

Cao

Xing

et al. 2023

Clin Transl Oncol

View full text Add to dashboard Cite

The mechanism of deleted in lymphocytic leukemia 2 (DLEU2)-long non-coding RNA in tumors has become a major point of interest in recent research related to the occurrence and development of a variety of tumors. Recent studies have shown that the long non-coding RNA DLEU2 (lncRNA-DLEU2) can cause abnormal gene or protein expression by acting on downstream targets in cancers. At present, most lncRNA-DLEU2 play the role of oncogenes in different tumors, which are mostly associated with tumor characteristics, such as proliferation, migration, invasion, and apoptosis. The data thus far show that because lncRNA-DLEU2 plays an important role in most tumors, targeting abnormal lncRNA-DLEU2 may be an effective treatment strategy for early diagnosis and improving the prognosis of patients. In this review, we integrated lncRNA-DLEU2 expression in tumors, its biological functions, molecular mechanisms, and the utility of DLEU2 as an effective diagnostic and prognostic marker of tumors. This study aimed to provide a potential direction for the diagnosis, prognosis, and treatment of tumors using lncRNA-DLEU2 as a biomarker and therapeutic target.

show abstract

Cytogenetic Analysis of a Pseudoangiomatous Pleomorphic/Spindle Cell Lipoma

Abstract: Several acquired genomic aberrations were found in the tumor. Among them was loss of chromosome 13 material. Results confirm the (cyto)genetic similarity between pseudoangiomatous pleomorphic/spindle cell lipoma and spindle cell lipomas.

Cited by 6 publications

References 16 publications

lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR

lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR

Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2

Deleted in lymphocytic leukemia 2 (DLEU2): a possible biomarker that holds promise for future diagnosis and treatment of cancer

Contact Info

Product

Resources

About